Stomach cancer, also known as gastric cancer, is a formidable disease that continues to pose significant challenges in the realm of oncology. At Alfa Cytology, our team of seasoned biological experts has dedicated themselves to unraveling the intricate mechanisms underlying stomach cancer development and progression.
Introduction to Stomach Cancer
Stomach cancer is the 5th most common and the 5rd deadliest cancer worldwide, according to the latest report of the International Agency for research on Cancer. As a leading cause of cancer-related deaths worldwide, stomach cancer's burden extends far beyond its incidence, with its complex pathogenesis, cellular heterogeneity, and elusive therapeutic targets necessitating a multi-faceted approach to combat this deadly malignancy.
Current Therapies for Stomach Cancer
Despite the role of conventional treatments, the limited efficacy and toxicity have driven the search for more personalized therapies. The promising landscape of stomach cancer research has been fueled by a deeper understanding of the disease's pathogenesis and the emergence of cutting-edge technologies. Researchers and pharmaceutical companies are actively exploring novel therapeutic strategies, including targeted therapies, immunotherapies, and combination approaches, to overcome the limitations of traditional treatment modalities.
Below is a summary of molecules that can be used as potential biomarkers and therapeutic targets for stomach cancer.
| Molecule/Strategy |
Targets |
Known/Tested Use in Stomach Cancer |
| Anti-CA19-9 antibodies |
CA19-9 |
CA19-9-positive stomach cancer biomarker for diagnosis |
| Cetuximab |
EGFR |
Potential targeted therapy against tyrosine kinase receptors |
| Rilotumumab |
HGF |
Potential targeted therapy against tyrosine kinase receptors |
| Dovitinib |
VEGFR-1/2/3; PDGFR-β; FGFR1/2/3 |
Potential targeted therapy against tyrosine kinase receptors |
| Anti-FGFR2 antibodies |
FGFR2 |
Under clinical trial for FGFR2 overexpressing GC |
| Nimutuzumab |
EGFR |
Under clinical trial for EGFR high GC |
| Everolimus |
mTOR pathway |
Under clinical trial for MSI type GC with activating mutations of mTOR pathway members |
| Anti-HDGF antibodies |
HDGF |
Potential prognostic marker & target of H. pylori-induced GC |
| AMS 337 |
c-Met |
Positive results in Phase I clinical trial |
| Exosomes-delivered c-Met siRNA |
c-Met |
Potential use as therapy in combination with chemotherapy |
| BST2 siRNA |
BST2 |
Inhibits GC cell proliferation and motility – potential anti-GC therapy |
| Anti-CEACAM6 antibodies |
CEACAM6 |
Potential endoscopic marker for early GC diagnosis |
Our Services
This surge in market size underscores the increasing demand for effective and innovative therapy solutions. At Alfa Cytology, we are committed to advancing the field of stomach cancer research and translating cutting-edge scientific discoveries into tangible clinical benefits. Our comprehensive suite of services encompasses the full spectrum of preclinical research, from
target identification and validation to the evaluation of novel therapeutic strategies.
We provide one-stop solutions for stomach cancer, including but not limited to the following.
Modeling Services of Stomach Cancer
Studying the complexities of stomach cancer requires the utilization of robust and clinically relevant experimental models. At Alfa Cytology, we have established a comprehensive array of in vitro and in vivo models that faithfully recapitulate the diverse facets of gastric malignancies, from the genomic and molecular landscapes to the intricate tumor-microenvironment interactions.
From building customized in vitro and in vivo models to conducting comprehensive preclinical studies, Alfa Cytology strives to help clients accelerate the development of novel therapeutic strategies. Our cancer experts have many years of experience in the development of the latest therapies for stomach cancer. If you are interested in our service, please contact us.
For research use only.
Related Services
